Animal Health Company Seeks Federal Pentobarbital Import Approval
Published Date: 11/5/2026
Notice
Summary
Diamond Animal Health, Inc. wants to become an official importer of a controlled drug called Pentobarbital, which is used in animal health. People who make or use these drugs can share their thoughts or ask for a hearing by December 7, 2026. This move could affect businesses handling these substances and involves careful government review but no direct costs mentioned yet.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 2 costs, 1 mixed.
No Authorization to Import Finished Dosage Forms for Sale
The agency states that authorization will not extend to the import of Food and Drug Administration‑approved or non‑approved finished dosage forms for commercial sale. This prohibition applies to finished-dose products rather than bulk pentobarbital for manufacture.
Application to Import Pentobarbital Filed
On February 19, 2026, Diamond Animal Health, Inc. applied to be registered to import pentobarbital (controlled substance code 2270, Schedule II). The application states the import would support manufacture of the Schedule III (N) finished dosage form Euthasol.
Import Use Limited to Euthasol Manufacture
The notice states the company plans to import pentobarbital specifically to support manufacture of the Schedule III (N) finished dosage form Euthasol and that no other activity for this drug code is authorized under the registration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22553, Importer of Controlled Substances Application: Noramco
Noramco wants to become an official importer of some controlled substances like marijuana and methadone. People who make or apply to handle these drugs can share their thoughts or ask for a hearing by December 7, 2026. This move could affect companies dealing with these substances and involves a formal review process with no immediate cost changes announced.
2026-22289, Bulk Manufacturer of Controlled Substances Application: AJNA Biosciences
AJNA Biosciences wants to become a big-time producer of marijuana and related substances for research and clinical trials. This means they’ll grow and handle these controlled substances under strict rules, helping science move forward. If you have thoughts or objections, you’ve got until January 4, 2027, to speak up!
Previous / Next Documents
Previous: 2026-22554, Tribal Intergovernmental Advisory Committee Request for Member Nominations; Extension of Comment Period
HUD is giving tribes and interested folks 30 more days to nominate members for the Tribal Intergovernmental Advisory Committee. If you want to help shape housing programs for Native communities, now’s your chance! Just submit your nominations online by December 4, 2026—no mail or fax allowed.
Next: 2026-22556, Bulk Manufacturer of Controlled Substances Application: Navinta LLC
Navinta LLC wants to become a big-time maker of a strong medicine called Remifentanil, which is tightly controlled by the government. People and companies involved with this drug can share their thoughts or ask for a hearing by January 4, 2027. This move could affect how this medicine is made and shared, but no extra activities are allowed beyond manufacturing.